Literature DB >> 8018118

Rapid increase of blood pressure in extremely low birth weight infants after a single dose of dexamethasone.

A Fauser1, F Pohlandt, P Bartmann, L Gortner.   

Abstract

Blood pressure was retrospectively studied in all 22 extremely low birth weight infants (ELBW) (birth weight median 720 g, range 450-1020 g) who were admitted between July 1989 and October 1991 and received dexamethasone on days 2-25 (median 10) because of bronchopulmonary dysplasia or since lung function had not improved after installation of bovine surfactant. The average blood pressure during the 4 h before dexamethasone increased significantly (median individual increase 8 mmHg, P = 0.0005) until 8-12h thereafter. In addition to the lung disease, ten infants showed severe arterial hypotension with prolonged capillary refilling time ( > 3s) and oliguria and needed continuous infusion of epinephrine to increase blood pressure and urinary flow after treatment with colloids, dopamine and dobutamine had proved ineffective. Epinephrine infusion could be stopped in eight infants 8 h after dexamethasone administration. In ELBW infants blood pressure rose 8-12 h after a single dose of 0.25 mg/kg dexamethasone. In ELBW infants suffering from arterial hypotension who do not respond to infusion of colloids and catecholamines, dexamethasone may represent a new therapeutic tool.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8018118     DOI: 10.1007/bf01956753

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  17 in total

1.  Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Collaborative Dexamethasone Trial Group.

Authors: 
Journal:  Pediatrics       Date:  1991-09       Impact factor: 7.124

2.  Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study.

Authors:  T F Yeh; J A Torre; A Rastogi; M A Anyebuno; R S Pildes
Journal:  J Pediatr       Date:  1990-08       Impact factor: 4.406

3.  Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia.

Authors:  G B Avery; A B Fletcher; M Kaplan; D S Brudno
Journal:  Pediatrics       Date:  1985-01       Impact factor: 7.124

4.  Catecholamine-induced desensitization of brain beta adrenoceptors in vivo and reversal by corticosterone.

Authors:  E A Stone; M Egawa; C M Colbjornsen
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

5.  Glucocorticoid modulation of beta-adrenergic receptors of cultured rat arterial smooth muscle cells.

Authors:  A Jazayeri; W J Meyer
Journal:  Hypertension       Date:  1988-10       Impact factor: 10.190

6.  Reversal of human lymphocyte beta-adrenoceptor desensitization by glucocorticoids.

Authors:  K K Hui; M E Conolly; D P Tashkin
Journal:  Clin Pharmacol Ther       Date:  1982-11       Impact factor: 6.875

7.  Dexamethasone and hypertension in preterm infants.

Authors:  A Greenough; E F Emery; H R Gamsu
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

8.  [Dexamethasone therapy in bronchopulmonary dysplasia].

Authors:  U Merz; G Kuehl; O Linderkamp
Journal:  Klin Padiatr       Date:  1989 Jan-Feb       Impact factor: 1.349

9.  Terbutaline-induced desensitization of human lymphocyte beta 2-adrenoceptors. Accelerated restoration of beta-adrenoceptor responsiveness by prednisone and ketotifen.

Authors:  O E Brodde; M Brinkmann; R Schemuth; N O'Hara; A Daul
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

10.  Dexamethasone in the treatment of bronchopulmonary dysplasia.

Authors:  F Benini; F F Rubaltelli; P Griffith; M Sala; C Zorzi
Journal:  Acta Paediatr Scand Suppl       Date:  1989
View more
  11 in total

Review 1.  Corticosteroids for treating hypotension in preterm infants.

Authors:  Hafis Ibrahim; Ian P Sinha; Nimish V Subhedar
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

2.  Randomised trial of dopamine compared with hydrocortisone for the treatment of hypotensive very low birthweight infants.

Authors:  D Bourchier; P J Weston
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-05       Impact factor: 5.747

3.  Refractory hypotension in preterm infants with adrenocortical insufficiency.

Authors:  P C Ng; C W Lam; T F Fok; C H Lee; K C Ma; I H Chan; E Wong
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-03       Impact factor: 5.747

4.  Blood pressure in low birth weight infants after dexamethasone.

Authors:  D P Derleth
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

5.  Blood pressure in low birth weight infants after dexamethasone.

Authors:  C R Rosenfeld
Journal:  Eur J Pediatr       Date:  1994-04       Impact factor: 3.183

6.  Reference range for serum cortisol in well preterm infants.

Authors:  M Heckmann; S A Wudy; D Haack; F Pohlandt
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-11       Impact factor: 5.747

7.  Transient adrenocortical insufficiency of prematurity and systemic hypotension in very low birthweight infants.

Authors:  P C Ng; C H Lee; C W K Lam; K C Ma; T F Fok; I H S Chan; E Wong
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-03       Impact factor: 5.747

8.  Clinical characterization and long-term prognosis of neurological development in preterm infants with late-onset circulatory collapse.

Authors:  H Nakanishi; S Yamanaka; T Koriyama; N Shishida; N Miyagi; T-J Kim; S Kusuda
Journal:  J Perinatol       Date:  2010-04-01       Impact factor: 2.521

9.  Dexamethasone associated systemic hypertension in low birth weight babies with chronic lung disease.

Authors:  K Smets; P Vanhaesebrouck
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

10.  Neonatal Dexamethasone Treatment Suppresses Hippocampal Estrogen Receptor α Expression in Adolescent Female Rats.

Authors:  Hui-Fang Chiu; Michael W Y Chan; Chiung-Yin Cheng; Jian-Liang Chou; Jora Meng-Ju Lin; Yi-Ling Yang; Kwok-Tung Lu
Journal:  Mol Neurobiol       Date:  2018-07-13       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.